文献速递艾滋病与性传播感染细菌感染、耐药与抗菌药物

坦桑尼亚接受抗逆转录病毒治疗的儿童和成人中新出现的整合酶链转移抑制剂耐药突变:一项具有全国代表性的HIV耐药调查结果

Emerging integrase strand transfer inhibitor drug resistance mutations among children and adults on ART in Tanzania: findings from a national representative HIV drug resistance survey.
PubMed 文献 · J Antimicrob Chemother · 2023-01-01

坦桑尼亚全国横断面HIV耐药调查对866名儿童和1173名成人中病毒载量≥1000拷贝/mL者进行基因型检测,137人(92名儿童、45名成人)完成检测,总体耐药突变患病率71.5%,儿童78.3%、成人57.8%,5.8%携带整合酶链转移抑制剂耐药突变。

要点

  • 病毒载量≥1000拷贝/mL者中,总体HIV耐药突变患病率为71.5%。
  • 儿童耐药突变患病率78.3%,成人57.8%。
  • 5.8%参与者携带整合酶链转移抑制剂耐药突变,包括Q148K、E138K、G118R、G140A、T66A和R263K等主要突变。

核心结论

  • 坦桑尼亚病毒载量高的患者中超过七成携带耐药突变,多替拉韦耐药的早期出现令人担忧,可能影响坦桑尼亚ART项目的疗效。

研究设计与样本

  • 全国横断面HIV耐药调查,纳入866名儿童和1173名成人,对病毒载量≥1000拷贝/mL者的干血斑和/或血浆进行基因型检测,用PCR扩增HIV逆转录酶、蛋白酶和整合酶基因并直接测序,采用斯坦福HIV耐药数据库判读。

主要发现

  • 对137名病毒载量≥1000拷贝/mL的参与者(92名儿童、45名成人)进行HIV耐药基因型检测,总体耐药突变患病率为71.5%,儿童为78.3%,成人为57.8%。
  • 5.8%的参与者携带整合酶链转移抑制剂耐药突变,包括主要突变Q148K、E138K、G118R、G140A、T66A和R263K。
  • 非核苷类逆转录酶抑制剂、核苷类逆转录酶抑制剂和蛋白酶抑制剂耐药突变分别见于62.8%、44.5%和8%的参与者。
  • 所有携带主要整合酶链转移抑制剂耐药突变的参与者均同时携带针对核苷类逆转录酶抑制剂骨干药物的耐药突变。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Despite the scale-up of ART and the rollout in Tanzania of dolutegravir, an integrase strand transfer inhibitor (INSTI), treatment success has not been fully realized. HIV drug resistance (HIVDR), including dolutegravir resistance, could be implicated in the notable suboptimal viral load (VL) suppression among HIV patients. OBJECTIVES: To determine the prevalence and patterns of acquired drug resistance mutations (DRMs) among children and adults in Tanzania. METHODS: A national cross-sectional HIVDR survey was conducted among 866 children and 1173 adults. Genotyping was done on dried blood spot and/or plasma of participants with high HIV VL (≥1000 copies/mL). HIV genes (reverse transcriptase, protease and integrase) were amplified by PCR and directly sequenced. The Stanford HIVDR Database was used for HIVDR interpretation. RESULTS: HIVDR genotyping was performed on blood samples from 137 participants (92 children and 45 adults) with VL ≥ 1000 copies/mL. The overall prevalence of HIV DRMs was 71.5%, with DRMs present in 78.3% of children and 57.8% of adults. Importantly, 5.8% of participants had INSTI DRMs including major DRMs: Q148K, E138K, G118R, G140A, T66A and R263K. NNRTI, NRTI and PI DRMs were also detected in 62.8%, 44.5% and 8% of participants, respectively. All the participants with major INSTI DRMs harboured DRMs targeting NRTI backbone drugs. CONCLUSIONS: More than 7 in 10 patients with high HIV viraemia in Tanzania have DRMs. The early emergence of dolutegravir resistance is of concern for the efficacy of the Tanzanian ART programme.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Kamori D, Barabona G, Rugemalila J, et al. Emerging integrase strand transfer inhibitor drug resistance mutations among children and adults on ART in Tanzania: findings from a national representative HIV drug resistance survey. J Antimicrob Chemother. 2023. PMID: 36680436. doi:10.1093/jac/dkad010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。